Acceleron  

Publications

  • Publication
    Sotatercept
    Dec 7, 2015
    Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Nov 6, 2015
    Safety and Hemoglobin Effect of Sotatercept, Administered Intravenously and Subcutaneously, for Maintenance of Hemoglobin in Hemodialysis Subjects: Interim Analysis of a Phase 2 Study. The 48th Annual American Society of Nephrology Kidney Week; November 6, 2015.
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Nov 5, 2015
    Sotatercept Improves Anemia, Vascular Calcification, and Bone Loss in Patients With End-Stage Kidney Disease on Hemodialysis. American Society of Nephrology Kidney Week 2015; November 5, 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Sep 18, 2015
    Sotatercept (ACE-011) for the Treatment of Chemotherapy-Induced Anemia in Patients with Metastatic Breast Cancer or Advanced or Metastatic Solid Tumors Treated with Platinum-Based Chemotherapeutic Regimens: Results from Two Phase 2 Studies. Supportive Care in Cancer 2015; published online Sept 14, ...
    + VIEW FULL Publication
  • Publication
    Sotatercept
    May 30, 2015
    Quantitative Computed Tomography Results for Bone Mass and Abdominal Aortic Vascular Calcification in Hemodialysis Subjects Treated With Escalating Dose Levels of Sotatercept: Interim Analysis of ACE-011-REN-001. 52nd ERA-EDTA Congress; May 30, 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    May 29, 2015
    Long-term Effects of 3 Dose Levels of Sotatercept Compared With Placebo for Correction of Anemia in Hemodialysis Subjects: Interim Analysis of ACE-011-REN-001. 52nd ERA-EDTA Congress; May 29, 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    May 29, 2015
    The Role of Activin Signaling in the Pathogenesis of Renal Osteodystrophy of CKD-MBD. 52nd ERA-EDTA Congress; May 29, 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Apr 29, 2015
    Oral Presentation – A Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. 13th International Symposium on Myelodysplastic Syndromes (MDS)...
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Dec 7, 2014
    An Open-Label, Phase 2, Dose-Finding Study of Sotatercept in Patients With Low- or Intermediate-1-Risk Myelodysplastic Syndromes or Non-Proliferative Chronic Myelomonocytic Leukemia and Anemia Requiring Transfusion. 56th American Society of Hematology Annual Meeting and Exposition; December 7, 2014
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Nov 13, 2014
    Safety and Hemoglobin Effect of the First 28-Day Dose Cycle of Sotatercept 0.7 mg/kg Compared With Lower Doses and Placebo for Correction of Anemia in Hemodialysis Subjects: Interim Analysis. American Society of Nephrology Kidney Week 2014; November 13, 2014
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Nov 13, 2014
    Sotatercept: Results for Bone Mass and Vascular Calcification in Hemodialysis Subjects Treated With Escalating Doses: Interim Analysis of ACE-011-REN-001. American Society of Nephrology Kidney Week 2014; November 13, 2014
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Jun 1, 2014
    Long-term Effects of Sotatercept Compared With Placebo for Correction of Anemia in Hemodialysis Subjects: Interim Analysis of ACE-011-REN-001 Phase 2A Study. 51st ERA-EDTA Congress; May 31-June 1, 2014
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Apr 23, 2014
    Interim Analysis of ACE-011-REN-001: The First 28 Day Dose Cycle of Low and Medium Starting Doses of Sotatercept Compared to Placebo for Correction of Anemia in Hemodialysis Subjects. Poster #81, National Kidney Foundation (NKF) 2014 Spring Clinical Meeting
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Apr 17, 2014
    Targeting a New Regulator of Erythropoiesis to Alleviate Anemia. Nature Medicine. April 2014; 20(4):334-35
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Mar 25, 2014
    An Activin IIa Ligand Trap Corrects Ineffective Erythropoiesis in β-Thalassemia. Nature Medicine 2014; published online March 23, 2014
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Mar 21, 2014
    Sotatercept in Patients with Osteolytic Lesions of Multiple Myeloma. British Journal of Haematology 2014; published online March 21, 2014
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Mar 18, 2014
    An Activin Receptor IIA Ligand Trap Promotes Erythropoiesis Resulting in a Rapid Induction of Red Blood Cells and Haemoglobin. British Journal of Haematology 2014; published online March 18, 2014
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Dec 9, 2013
    A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)-Thalassemia: Interim Results. Blood 2013; 122:3448
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Aug 16, 2013
    Multiple-Dose, Safety, Pharmacokinetic, Pharmacodynamic Study of Sotatercept, a Novel Erythropoietic Agent, in Healthy Postmenopausal Women. J Clin Pharmacol. 2013 Nov; 53:1121-30
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Nov 7, 2012
    Activin receptor antagonists for cancer-related anemia and bone disease. Expert Opin Investig Drugs 2013; 22(1): 87-101
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Dec 1, 2010
    Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J. Bone Miner Res 2010; 25(12): 2633-46
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Oct 1, 2010
    Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 2010;12(5):586-97
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Apr 1, 2010
    A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010;46(4):1082-8
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Mar 16, 2010
    Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. PNAS 2010, 107(11): 5124-5129
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Jan 1, 2010
    Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone 2010;46(1):64-71
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Dec 1, 2008
    Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women. J Bone Min Res 2009;24:744–752
    + VIEW FULL Publication
  • Publication
    Sotatercept
    May 13, 2008
    A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. PNAS 2008; 105(19): 7082-7087
    + VIEW FULL Publication